华芢生物-B：稳定价格期间结束、无稳定价格行动及超额配股权失效

Group 1 - The stabilization period for the global offering of Huazhang Biotechnology-B (02396) ended on January 16, 2026, which is 30 days after the deadline for submitting the Hong Kong public offering application [1][4] - There was no over-allocation of shares under the international offering, and therefore, the over-allotment option was not exercised and has expired as of January 16, 2026 [1][4] - The company was informed by the stabilization agent that no stabilization actions were taken during the stabilization period [1][4]